Polyrizon Ltd Ordinary Shares

Yahoo Finance • 9 days ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre... Full story

Yahoo Finance • 16 days ago

Keep an eye on the top gainers and losers in Friday's session.

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GCTK [https://www.chartmill.... Full story

Yahoo Finance • 16 days ago

Which stocks are gapping on Friday?

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] GAP UP STOCKS TICKER CHANGE COMMENT OPI [https://w... Full story

Yahoo Finance • 16 days ago

Top movers in Friday's pre-market session

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT GCT... Full story

Yahoo Finance • 16 days ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Ra’anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical resul... Full story

Yahoo Finance • last month

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal co... Full story

Yahoo Finance • 2 months ago

Polyrizon's nasal allergy blocker shows promising deposition results

RA’ANANA, ISRAEL - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech company with a market capitalization of $4.84 million, announced Tuesday that its PL-14 Allergy Blocker demonstrated over 60% deposition in the nasal vestibule during pre... Full story

Yahoo Finance • 2 months ago

Polyrizon secures continued Nasdaq listing after panel hearing

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) has received approval from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market, the biotech company announced Tuesday. According to InvestingPro data, the micro-cap... Full story

Yahoo Finance • 2 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it h... Full story

Yahoo Finance • 4 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from... Full story

Yahoo Finance • 4 months ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it ha... Full story

Yahoo Finance • 4 months ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage... Full story

Yahoo Finance • 5 months ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced t... Full story

Yahoo Finance • 6 months ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today tha... Full story

Yahoo Finance • 6 months ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized brand... Full story

Yahoo Finance • 6 months ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placemen... Full story

Yahoo Finance • 6 months ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

RAANANA, ISRAEL, March 31, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into definitive agreements with ins... Full story

Yahoo Finance • 6 months ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company speciali... Full story

Yahoo Finance • 6 months ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or... Full story

Yahoo Finance • 7 months ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today th... Full story